---
title: "Indaptus Therapeutics, Inc. (INDP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INDP.US.md"
symbol: "INDP.US"
name: "Indaptus Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T10:34:53.454Z"
locales:
  - [en](https://longbridge.com/en/quote/INDP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INDP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INDP.US.md)
---

# Indaptus Therapeutics, Inc. (INDP.US)

## Company Overview

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [indaptusrx.com](https://indaptusrx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.16 | 86 | - | - | - |
| PB | 2.39 | 220 | 2.11 | 1.25 | 0.90 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-12T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.33 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/INDP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/INDP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/INDP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/INDP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**